Clinical trial
PTK787/ZK 222584 in Combination With Temozolomide and Radiation in Patients With…
NCT00385853 · Massachusetts General Hospital, Other · Completed
Key facts
| NCT number | NCT00385853 |
|---|---|
| Title | PTK787/ZK 222584 in Combination With Temozolomide and Radiation in Patients With Glioblastoma Taking Enzyme-Inducing Anti-Epileptic Drugs |
| Official title | A Phase I Study of PRK787/ZK 222584 in Combination With Daily Temozolomide and Radiation in Patients With Newly Diagnosed Glioblastoma |
| Lead sponsor | Massachusetts General Hospital, Other |
| Collaborators | Dana-Farber Cancer Institute Novartis Industry |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Glioblastoma |
| Intervention type | Drug, Procedure |
| Interventions | PTK787/ZK 222584, Temozolomide, Radiation Therapy |
| Enrollment | 19 |
| Start date | Sep 1, 2006 |
| Primary completion | Sep 1, 2011 |
| Completion | Sep 1, 2011 |
| First posted | Oct 11, 2006 |
| Last update posted | Oct 21, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: